Should we measure asymmetric dimethylarginine in patients with coronary artery disease?
نویسندگان
چکیده
In this issue of Clinical Chemistry, Meinitzer et al. (1 ) present data from The Ludwigshafen Risk and Cardiovascular Health Study in which they assess asymmetric dimethylarginine (ADMA) as a cardiovascular biomarker in 3238 patients. Coronary angiography identified 2543 patients with coronary artery disease as well as 695 persons without significant disease. Study participants were followed for more than 5 years. The major finding of the study was that plasma ADMA was an independent predictor of total and cardiovascular mortality.
منابع مشابه
Assessment of serum levels of asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine in coronary artery disease.
Serum asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), L-arginine, and C-reactive protein (hsCRP) levels were assessed in 100 Egyptian male 35-50-year-old patients with coronary artery disease (CAD), classified into: patients under conservative medical treatment, patients directed for percutaneous coronary interventions, patients directed for coronary artery bypass graft o...
متن کاملThe levels of asymmetric dimethylarginine in patients with isolated coronary artery ectasia
Aim: Although underlying mechanisms of coronary artery ectasia (CAE) are clearly unknown, endothelial dysfunction may be responsible for the coronary ectasia. Asymmetric dimethylarginine (ADMA) is the principal endogenous inhibitor of nitric oxide synthase and elevated levels of ADMA is considered to be a marker of endothelial dysfunction and increased risk of cardiovascular disease. Accordingl...
متن کاملSuppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine.
OBJECTIVES We tested the hypothesis that asymmetric dimethylarginine (ADMA) may be an endogenous inhibitor of endothelial progenitor cells (EPCs). BACKGROUND Endothelial progenitor cells play a pivotal role in regeneration of injured endothelium, thereby limiting the formation of atherosclerotic lesions. Reduced numbers of EPCs may affect progression of coronary artery disease. Regulation of ...
متن کاملPlasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty
INTRODUCTION Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of endothelial nitric oxide synthase. Asymmetric dimethylarginine may influence the process of restenosis after coronary angioplasty. The aim of the study was to determine if initial plasma ADMA level could predict restenosis after coronary angioplasty and stenting. MATERIAL AND METHODS The study group cons...
متن کاملSerum asymmetric dimethylarginine as a marker of coronary microcirculation in patients with non-insulin dependent diabetes mellitus: correlation with coronary flow reserve.
A bnormalities of coronary microcirculation without large vessel atherosclerosis have been known in patients with non-insulin dependent diabetes mellitus (NIDDM). Coronary flow reserve (CFR) has been considered an important physiological parameter in the coronary circulation reflecting the function of large epicardial arteries and the microcirculation, including endothelial function. Reduced CF...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical chemistry
دوره 53 2 شماره
صفحات -
تاریخ انتشار 2007